Abstract
With a large number of one-time administration cell and gene therapies expected to come to the market in the coming years, there is a renewed need to understand the existing and future challenges that such modalities bring about, especially as it relates to their assessment of value, pricing and access. Payer, health technology assessment (HTA) bodies and manufacturers alike are faced with a number of unprecedented challenges stemming from the fact that such therapies are ‘one-time’ and/or have curative intent, but often lack sufficient evidence to support such claims at the time of launch (i.e., during pricing and access negotiations). There are a number of different approaches to assessing economic value for cell and gene therapies across regions (e.g., US vs Europe), which ultimately lead to further disconnect in pricing and reimbursement outcomes across countries; yet, in many cases, affordability concerns relating to high upfront costs are raised by providers. To that end, cell and gene therapies have been frequently criticized by payers for their ‘high sticker price’ based on relatively limited evidence to support durability claims. New contracting solutions are increasingly being employed to overcome concerns specifically relating to the durability of clinical benefit, the comparative effectiveness of a therapy and affordability (i.e., the one-time high cost of therapy). Indeed, recent launches of cell and gene therapies have often leveraged outcome-based agreements, instalments, coverage with evidence generation, subscription models, stop-loss and payer reinsurance, etc. to mitigate concerns from payers and providers and drive access. In this paper, we aim to review challenges for cell and gene therapies from a pricing and access perspective and explore the growing role of innovative contracting solutions to overcome aforementioned challenges.
Similar content being viewed by others
References
Touchot N, Flume M. Early insights from commercialization of gene therapies in Europe. Genes (Basel). 2017;8:78. https://doi.org/10.3390/genes8020078.
Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273–88. https://doi.org/10.1146/annurev-med-012017-043332.
Dolgin E. “Bubble boy” gene therapy reignites commercial interest. Nat Biotechnol. 2019;37:699–701. https://doi.org/10.1038/d41587-019-00015-6.
Shahryari A, Jazi MS, Mohammadi S, et al. Development and clinical translation of approved gene therapy products for genetic disorders. Front Genet. 2019;10:868. https://doi.org/10.3389/fgene.2019.00868.
Salzman R, Cook D, Hunt T, et al. Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther. 2018;26:2717–26. https://doi.org/10.1016/j.ymthe.2018.10.017.
Hanna E, Remuzat R, Auquier P, et al. Gene therapies development: slow progress and promising prospect. J Mark Access Health Policy. 2017;5:1265293. https://doi.org/10.1080/20016689.2017.1265293.
Assessment Report for Glybera. European Medicines Agency https://www.ema.europa.eu/en/documents/assessment-report/glybera-epar-public-assessment-report_en.pdf. Accessed Jul 2022.
Assessment Report for Strimvelis. European Medicines Agency. https://www.ema.europa.eu/en/documents/assessment-report/strimvelis-epar-public-assessment-report_en.pdf. Accessed Jul 2022.
Assessment Report for Luxturna. European Medicines Agency. https://www.ema.europa.eu/en/documents/assessment-report/luxturna-epar-public-assessment-report_en.pdf. Accessed Jul 2022.
Assessment Report for Zolgensma. European Medicines Agency https://www.ema.europa.eu/en/documents/assessment-report/zolgensma-epar-public-assessment-report_en.pdf. Accessed Jul 2022.
Assessment Report for Kymriah. European Medicines Agency. https://www.ema.europa.eu/en/documents/assessment-report/kymriah-epar-public-assessment-report_en.pdf. Accessed Jul 2022.
Assessment Report for Yescarta. European Medicines Agency https://www.ema.europa.eu/en/documents/assessment-report/yescarta-epar-public-assessment-report_en.pdf. Accessed Jul 2022.
Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value." Office of Health Economics. https://www.ohe.org/publications/gene-therapy-understanding-science-assessing-evidence-and-paying-. Accessed Jul 2022.
Hampson G, Towse A, Pearson SD, et al. Gene Therapy: evidence, value and affordability in the us health care system. J Comp Eff Res. 2018;7:15–28. https://doi.org/10.2217/cer-2017-0068.
ICER Draws New Gene Therapy Pricing Framework. Biopharmadive. https://www.biopharmadive.com/news/icer-gene-therapy-one-time-pricing-framework/567249/. Accessed Jul 2022.
Qiu T, Hanna E, Dabbous M, et al. Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations. Cell and Gene Therapy Insights. 2019; 5:1043–59. https://insights.bio/cell-and-gene-therapy-insights/journal/article/115/Health-Technology-Assessment-of-Gene-Therapies-in-Europe-and-the-USA-Analysis-and-Future-Considerations. Accessed Jul 2022.
Glybera (Alipogene Tiparvovec). Haute Autorité De Santé. https://www.has-sante.fr/jcms/c_2579395/en/glybera-alipogene-tiparvovec-gene-therapy. Accessed Jul 2022.
Evaluation Consultation Document Strimvelis for Treating Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency. The National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/hst7/documents/evaluation-consultation-document. Access Jul 2022.
Yescarta (Axicabtagene Ciloleucel). Haute Autorité De Santé. https://www.has-sante.fr/jcms/c_2888882/fr/yescarta-axicabtagene-ciloleucel-car-t-anti-cd19. Accessed Jul 2022.
Kymriah (Tisagenlecleucel). Haute Autorité De Santé. https://www.has-sante.fr/jcms/c_2891692/fr/kymriah-tisagenlecleucel-car-t-anti-cd19-ldgcb. Accessed Jul 2022.
Luxturna (Voretigène Néparvovec). Haute Autorité De Santé. https://has-sante.fr/jcms/c_2964759/fr/luxturna. Accessed Jul 2022.
Commission De La Transparence Avis 16 Decembre 2020. Haute Autorité De Santé. https://has-sante.fr/upload/docs/evamed/CT-18743_ZOLGENSMA_PIC_INS_AvisDef_CT18743.pdf. Accessed Jul 2022.
Onasemnogene Abeparvovec for Treating Spinal Muscular Atrophy. The National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/hst15/documents/html-content-3. Accessed Jul 2022.
ASGCT Q2 2021 Quarterly Data Report. American Society of Gene and Cell Therapy. https://asgct.org/global/documents/asgct-pharma-intelligence-quarterly-report-july-20.aspx. Accessed Jul 2022.
Gilead: 'We Stand Behind the Pricing of Our Therapies. Biopharmadive. https://www.biopharmadive.com/news/gilead-we-stand-behind-the-pricing-of-our-therapies/423859/. Accessed Jul 2022.
The Price of Sovaldi and Its Impact on the U.S. Health Care System. United States Senate Committee on Finance. https://www.finance.senate.gov/imo/media/doc/2%20Introduction,%20Hepatitis%20C%20Background,%20Development%20of%20Sovaldi%20and%20Gilead's%20Acquistion%20of%20Pharmasset%20(Introduction,%20Sections%201&2).pdf. Accessed Jul 2022.
Pricing Pressures: How the Business of Medicine Affects the Price of Therapy. Healio. https://www.healio.com/news/hepatology/20151114/pricing-pressures-how-the-business-of-medicine-affects-the-price-of-therapy. Accessed Jul 2022.
Lehmicke M. Manufacturing Cures: Infrastructure Challenges Facing Cell and Gene Therapy Developers. http://alliancerm.org/wp-content/uploads/2019/06/Manufacturing-Cures-In-Vivo-PDF.pdf. Accessed Jul 2022.
Perica K, Curran KJ, Brentjens RJ, et al. Building a CAR garage: preparing for the delivery of commercial car T cell products at memorial sloan kettering cancer center. Biol Blood Marrow Transplant. 2018;24:1135–41. https://doi.org/10.1016/j.bbmt.2018.02.018.
Towse A, Fenwick E. It Takes Two to Tango: When Do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties? Setting out the Conditions in Which Risk Sharing Schemes Improve Value for Money. https://www.ohe.org/system/files/private/publications/Towse%20Fenwick%20post%20review%20final%20v2.pdf. Accessed Jul 2022.
Young CM, Quinn C, Trusheim MR. Durable cell and gene therapy potential patient and financial impact: us projections of product approvals, patients treated, and product revenues. Drug Discov Today. 2022;27:17–30. https://doi.org/10.1016/j.drudis.2021.09.001.
Towse A, Fenwick E. Uncertainty and cures: discontinuation, irreversibility, and outcomes-based payments: what is different about a one-off treatment? Value Health. 2019;22:677–83. https://doi.org/10.1016/j.jval.2019.03.013.
Avexis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families. Novartis. https://www.novartis.com/news/media-releases/avexis-announces-innovative-zolgensma-gene-therapy-access-programs-us-payers-and-families. Accessed Jul 2022.
Spark Therapeutics Announces First-of-Their-Kind Programs to Improve Patient Access to Luxturna™ (Voretigene Neparvovec-Rzyl), a One-Time Gene Therapy Treatment. Spark Therapeutics. https://sparktx.com/press_releases/spark-therapeutics-announces-first-of-their-kind-programs-to-improve-patient-access-to-luxturna-voretigene-neparvovec-rzyl-a-one-time-gene-therapy-treatment/. Accessed Jul 2022.
Hutton J, Trueman P, Henshall C. Coverage with Evidence Development: An Examination of Conceptual and Policy Issues. https://www.cambridge.org/core/journals/international-journal-of-technology-assessment-in-health-care/article/coverage-with-evidence-development-an-examination-of-conceptual-and-policy-issues/B6D93FF81E114BA6C91DE1DE232D2687. Accessed Jul 2022.
CMS Approves Louisiana's 'Netflix Model' Using Gilead Hepatitis C Drugs. Biopharmadive. https://www.biopharmadive.com/news/cms-approves-louisianas-netflix-model-with-gilead-for-hepatitis-c-drugs/557708/. Accessed Jul 2022.
Bohm N, Bermingham S, Jones FG, et al. The challenges of outcomes-based contract implementation for medicines in Europe. Pharmacoeconomics. 2022;40:13–29. https://doi.org/10.1007/s40273-021-01070-1.
Multiple RJ, Scheme SRS. A costly failure. BMJ. 2010;340: c1672. https://doi.org/10.1136/bmj.c1672.
Jorgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched car-t cell therapies in major European countries. J Mark Access Health Policy. 2020;8:1715536. https://doi.org/10.1080/20016689.2020.1715536.
AveXis Receives EC Approval and Activates “Day One” Access Program for Zolgensma®, the Only Gene Therapy for Spinal Muscular Atrophy (Sma). Novartis. https://www.novartis.com/news/media-releases/avexis-receives-ec-approval-and-activates-day-one-access-program-zolgensma-only-gene-therapy-spinal-muscular-atrophy-sma. Accessed Jul 2022.
EC Approval and Activation of “Day One” Access Program for Zolgensma in SMA". The pharma letter. https://www.thepharmaletter.com/article/ec-approval-and-activation-of-day-one-access-program-for-zolgensma-in-sma. Access Jul 2022.
The Health Economics & Market Access (HE&MA) Function of the (CGT) Cell and Gene Therapy Catapult. Cell and Gene Therapy Catapult. https://ct.catapult.org.uk/sites/default/files/publication/The%20Cell%20and%20Gene%20Therapy%20Catapult%20approach%20to%20pricing%20and%20reimbursement%20strategy%20development.pdf. Accessed Jul 2022.
Pearson SD, Ollendorf DA, Chapman RH. New cost-effectiveness methods to determine value-based prices for potential cures: what are the options? Value Health. 2019;6:656–60. https://doi.org/10.1016/j.jval.2019.01.012.
Emicizumab for Hemophilia a with Inhibitors: Effectiveness and Value. Institute For Clinical And Economic Review. https://icer.org/wp-content/uploads/2020/10/ICER_Hemophilia_Final_Evidence_Report_041618.pdf. Accessed Jul 2022.
CHTE Methods Review: Task and Finish Group Report // Technology-Specific Issues, Technology Specific Issues Task and Finish Group Report. The National Institute for Health and Care Excellence. https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/nice-guidance/chte-methods-consultation/Technology-specific-issues-task-and-finish-group-report.docx. Accessed Jul 2022.
Garrison LP, Jiao B, Dabbous O. Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies. J Manag Care Spec Pharm. 2021;27:674–81. https://doi.org/10.18553/jmcp.2021.27.5.674.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding was received for this publication.
Conflicts of interest
Authors are employees of E&Y and have been involved in and/or exposed to a number of engagements for both public bodies (healthcare provides) and private bodies (pharma/biotech companies).
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data and material
Not applicable.
Code availability
Not applicable.
Authors' contributions
MTS conceived the research, analyzed the data, performed the literature search. MTS, TX and MC jointly wrote the manuscript and critically revised the work. All authors have read and approve the final manuscript and agree to be accountable for this work.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Sabatini, M.T., Xia, T. & Chalmers, M. Pricing and Market Access Challenges in the Era of One-Time Administration Cell and Gene Therapies. Pharm Med 36, 265–274 (2022). https://doi.org/10.1007/s40290-022-00443-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40290-022-00443-x